NCT01093196: Phase 3: EMN01- Len/Dex Vs Melphalan/Pred/Len Vs Cyclophosamide/Pred/Len - elderly NDMM
- Active, not recruiting
- Dec 16, 2010
- 2 min read
Updated: Sep 25, 2022
EMN01
European Myeloma Network
Newly Diagnosed Multiple Myeloma
NCT01093196: Phase 3: Len and Dex Vs Melphalan Prednisone and Len Vs Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients
NCT01093196: Phase 3: Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients
This is a multicenter, randomized, controlled, 3 arm parallel group study designed to evaluate the efficacy and safety of three all-oral combinations: lenalidomide with dexamethasone (Rd) in comparison with lenalidomide in association with MP (MPR) and lenalidomide in association with cyclophosphamide - prednisone (CPR) in newly diagnosed symptomatic MM patients. This protocol also provides a substudy designed to observe asymptomatic patients excluded to the protocol that in any case could be inserted in the study.
Sponsor
Fondazione EMN Italy Onlus
ClinicalTrials.gov Identifier: NCT01093196
Official Title: A Phase 3, Intergroup Multicentre, Randomized, Controlled 3 Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide in Combination With Dexamethasone (RD) Versus Melphalan, Prednisone and Lenalidomide (MPR) Versus Cyclophosphamide, Prednisone and Lenalidomide (CPR) in Newly Diagnosed Elderly Multiple Myeloma Subjects
First Posted : March 25, 2010
Click here for details on ClinicalTrials.gov
Drug: Melphalan, Prednisone, Lenalidomide
Drug: Cyclophosphamide, Prednisone, Lenalidomide
Drug: Lenalidomide, dexamethasone
Blood; 2015
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
Blood;2016
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma
Haematologica; 2020
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial
Haematologica; 2020
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs
MYELOMA FRAILTY SCORE CALCULATOR
